Download PDF
Arzneimittelforschung 2012; 62(02): 53-58
DOI: 10.1055/s-0031-1299685
Review
© Georg Thieme Verlag KG Stuttgart · New York

The Pharmacological Profile and Clinical Use of Mesalazine (5-Aminosalicylic Acid)

U. Klotz
1   Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany
› Author Affiliations
Further Information

Publication History

received 25 October 2011

accepted 01 December 2011

Publication Date:
16 February 2012 (online)

    Permissions and Reprints

Abstract

For more than 30 years mesalazine (5-aminosalicylic acid; 5-ASA) has been used for the treatment of chronic inflammatory bowel disease (IBD) especially in ulcerative colitis (UC). During this time various rectal and oral formulations have been developed. The modified drug delivery systems were designed to release sufficient 5-ASA at the sites of inflammation. Such a drug targeting strategy is needed for its topical action and especially because local concentrations in the mucosa will determine the clinical outcome. The absorbed part (20–40% of the dose) of 5-ASA is rapidly and presystemically acetylated (t1/2: 1–2.5 h; CL: 300–690 mL/min). Consequently, the systemic exposure of 5-ASA is low and adverse effects are in the range of placebo treatment. The polypotent 5-ASA has a wide spectrum of pharmacological properties and its exact mode of action is not yet clear. Recent meta-analyses of randomized placebo-controlled clinical trials provide convincing data that 5-ASA is the preferred first-line therapy for the acute treatment of mild-to-moderate UC (NNT:6) and for remission management (NNT:4). There is also some clinical benefit for patients with active Crohn’s disease (NNT:7) and in the prevention of postsurgical relapse (NNT:10). There is increasing evidence that 5-ASA also has some therapeutic potential for chemoprevention of colorectal cancer, diverticular disease and irritable bowel syndrome. In all clinical studies, the side effects of 5-ASA were very low (5–10%), mild and comparable to placebo. Thus, its use is very safe and 5-ASA will remain an interesting and valuable agent. It is anticipated that more selective drug targeting, including galenic innovations and an optimized dosaging schedule, could result in some improvement of the wide use of 5-ASA.

Key words

mesalazine - 5-aminosalicylic acid - chronic inflammatory bowel disease - ulcerative colitis - Crohn’s disease - pharmacological properties - therapeutic efficacy - clinical safety
 

  • References

  • 1 Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892-895
    PubMedGoogle Scholar
  • 2 Van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 632-635
    CrossrefPubMedGoogle Scholar
  • 3 Klotz U, Maier K, Fischer C et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. N Engl J Med 1980; 303: 1499-1502
    CrossrefPubMedGoogle Scholar
  • 4 Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 996-1009
    CrossrefPubMedGoogle Scholar
  • 5 Fiocchi C. Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand?. Dig Dis 2009; 27: 226-235
    CrossrefPubMedGoogle Scholar
  • 6 Fiocchi C. The multiple components of inflammatory bowel disease pathogenesis: should we invest in all of them or should we pick and choose?. Curr Opin Gastroenterol 2005; 21: 399-400
    PubMedGoogle Scholar
  • 7 Sandborn WJ. What’s new: innovative concepts in inflammatory bowel disease. Colorectal Dis 2006; 8 (Suppl. 01) 3-9
    PubMedGoogle Scholar
  • 8 Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-1592
    CrossrefPubMedGoogle Scholar
  • 9 Hoentjen F, Sakuraba A, Hanauer S. Update on the management of ulcerative colitis. Curr Gastroenterol Rep 2011; 13: 475-485
    CrossrefPubMedGoogle Scholar
  • 10 Egan LJ, Sandborn WJ. Advances in the treatment of Crohn’s disease. Gastroenterology 2004; 126: 1574-1581
    CrossrefPubMedGoogle Scholar
  • 11 Buchner AM, Blonski W, Lichtenstein GR. Update on the management of Crohn’s disease. Curr Gastroenterol Rep 2011; 13: 465-474
    CrossrefPubMedGoogle Scholar
  • 12 Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57: 267-279
    CrossrefPubMedGoogle Scholar
  • 13 Klotz U. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig Liver Dis 2005; 37: 381-388
    CrossrefPubMedGoogle Scholar
  • 14 Safdi M, DeMicco M, Sninsky C et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-1871
    PubMedGoogle Scholar
  • 15 Paoluzi P, d’Albasio G, Pera A et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis 2002; 34: 787-793
    CrossrefPubMedGoogle Scholar
  • 16 Yokoyama H, Takagi S, Kuriyama S et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007; 13: 1115-1120
    CrossrefPubMedGoogle Scholar
  • 17 Sonu I, Lin MV, Blonski W et al. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol Clin North Am 2010; 39: 559-599
    CrossrefPubMedGoogle Scholar
  • 18 Williams C, Panaccione R, Ghosh S et al. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Ther Adv Gastroenterol 2011; 4: 237-248
    CrossrefPubMedGoogle Scholar
  • 19 Yang LP, McCormack PL. MMX(®)Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis. Drugs 2011; 71: 221-235
    CrossrefPubMedGoogle Scholar
  • 20 Prantera C, Rizzi M. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009; 15: 4353-4355
    CrossrefPubMedGoogle Scholar
  • 21 Oliveira L, Cohen RD. Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine. Drug Des Devel Ther 2011; 5: 111-116
    PubMedGoogle Scholar
  • 22 Hu MY, Peppercorn MA. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. Expert Opin Pharmacother 2008; 9: 1049-1058
    CrossrefPubMedGoogle Scholar
  • 23 Frieri G, Pimpo MT, Andreoli A et al. Prevention of post-operative recurrence of Crohn’s disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto. Aliment Pharmacol Ther 1999; 13: 577-582
    CrossrefPubMedGoogle Scholar
  • 24 Frieri G, Giacomelli R, Pimpo M et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47: 410-414
    CrossrefPubMedGoogle Scholar
  • 25 Naganuma M, Iwao Y, Ogata H et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 2001; 7: 221-225
    CrossrefPubMedGoogle Scholar
  • 26 Frieri G, Pimpo MT, Palumbo GC et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 1999; 13: 1413-1417
    CrossrefPubMedGoogle Scholar
  • 27 d’Albasio G, Pacini F, Camarri E et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143-1147
    PubMedGoogle Scholar
  • 28 Marteau P, Probert CS, Lindgren S et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-965
    CrossrefPubMedGoogle Scholar
  • 29 König J, Glaeser H, Keiser M et al. Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos 2011; 39: 1097-1102
    CrossrefPubMedGoogle Scholar
  • 30 Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 723-751
    CrossrefPubMedGoogle Scholar
  • 31 MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 2000; 95: 3343-3345
    CrossrefPubMedGoogle Scholar
  • 32 Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment Pharmacol Ther 2006; 24 (Suppl. 01) 2-9
    PubMedGoogle Scholar
  • 33 Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010; 31: 202-209
    PubMedGoogle Scholar
  • 34 Garud S, Brown A, Cheifetz A et al. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008; 53: 875-891
    CrossrefPubMedGoogle Scholar
  • 35 Ford AC, Achkar JP, Khan KJ et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-616
    CrossrefPubMedGoogle Scholar
  • 36 Ford AC, Kane SV, Khan KJ et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 617-629
    CrossrefPubMedGoogle Scholar
  • 37 Ford AC, Khan KJ, Talley NJ et al. 5-aminosalicylates prevent relapse of Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 413-420
    CrossrefPubMedGoogle Scholar
  • 38 Kane S. Does treatment schedule matter? Once daily versus divided doses of 5-ASAs. Dig Dis 2010; 28: 478-482
    CrossrefPubMedGoogle Scholar
  • 39 Moum B. Which are the 5-ASA compound side effects and how is it possible to avoid them?. Inflamm Bowel Dis 2008; 14 (Suppl. 02) S212-S213
    CrossrefPubMedGoogle Scholar
  • 40 Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539
    CrossrefPubMedGoogle Scholar
  • 41 Di Paolo MC, Paoluzi OA, Pica R et al. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Dig Liver Dis 2001; 33: 563-569
    CrossrefPubMedGoogle Scholar
  • 42 Klotz U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 2000; 56: 353-362
    CrossrefPubMedGoogle Scholar
  • 43 Loftus Jr EV, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 179-189
    CrossrefPubMedGoogle Scholar
  • 44 Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (Suppl. 02) 15-21
    CrossrefPubMedGoogle Scholar
  • 45 Diener U, Tuczek HV, Fischer C et al. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol 1984; 326: 278-282
    CrossrefPubMedGoogle Scholar
  • 46 Herrlinger KR, Noftz MK, Fellermann K et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 2001; 15: 363-369
    CrossrefPubMedGoogle Scholar
  • 47 Fraser JS, Muller AF, Smith DJ et al. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 2001; 15: 1131-1137
    CrossrefPubMedGoogle Scholar
  • 48 Mahmud N, O’Toole D, O’Hare N et al. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 207-215
    CrossrefPubMedGoogle Scholar
  • 49 Dehmer C, Greinwald R, Loffler J et al. No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases. Int J Colorectal Dis 2003; 18: 406-412
    CrossrefPubMedGoogle Scholar
  • 50 Van Staa TP, Travis S, Leufkens HG et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004; 126: 1733-1739
    CrossrefPubMedGoogle Scholar
  • 51 Müller AF, Stevens PE, McIntyre AS et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 2005; 21: 1217-1224
    CrossrefPubMedGoogle Scholar
  • 52 de Jong DJ, Tielen J, Habraken CM et al. 5-Aminosalicylates and effects on renal function in patients with Crohn’s disease. Inflamm Bowel Dis 2005; 11: 972-976
    CrossrefPubMedGoogle Scholar
  • 53 Lukas M. Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis 2010; 28: 619-624
    CrossrefPubMedGoogle Scholar
  • 54 Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-1353
    CrossrefPubMedGoogle Scholar
  • 55 Tang J, Sharif O, Pai C et al. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci 2010; 55: 1696-1703
    CrossrefPubMedGoogle Scholar
  • 56 Bernstein CN, Nugent Z, Blanchard JF. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011; 106: 731-736
    CrossrefPubMedGoogle Scholar
  • 57 Terdiman JP. The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven. Am J Gastroenterol 2011; 106: 737-740
    CrossrefPubMedGoogle Scholar
  • 58 Tursi A. Mesalazine for diverticular disease of the colon – a new role for an old drug. Expert Opin Pharmacother 2005; 6: 69-74
    CrossrefPubMedGoogle Scholar
  • 59 Comparato G, Fanigliulo L, Cavallaro LG et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 2007; 52: 2934-2941
    CrossrefPubMedGoogle Scholar
  • 60 Gatta L, Di Mario F, Curlo M et al. Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. Intern Emerg Med 2011; Epub Jan 29
    PubMedGoogle Scholar
  • 61 Tursi A, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci 2011; 56: 3112-3121
    CrossrefPubMedGoogle Scholar
  • 62 Gatta L, Vakil N, Vaira D et al. Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol 2010; 44: 113-119
    CrossrefPubMedGoogle Scholar
  • 63 Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245-252
    CrossrefPubMedGoogle Scholar
  • 64 Andrews CN, Griffiths TA, Kaufman J et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 374-383
    CrossrefPubMedGoogle Scholar
  • 65 Bafutto M, Almeida JR, Leite NV et al. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arq Gastroenterol 2011; 48: 36-40
    CrossrefPubMedGoogle Scholar
  • 66 Dorofeyev AE, Kiriyan EA, Vasilenko IV et al. Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol 2011; 4: 141-153
    CrossrefPubMedGoogle Scholar
  • 67 Jamma S, Leffler DA, Dennis M et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30-33
    CrossrefPubMedGoogle Scholar
  • 68 Green PH, Lebwohl B. Mesalamine for refractory celiac disease: an old medicine for a new disease. J Clin Gastroenterol 2011; 45: 1-3
    CrossrefPubMedGoogle Scholar